Tag Archives: Concert Pharmaceuticals

← Older posts Newer posts →

East Coast Biotech Roundup: Biogen, Civitas, Rhythm, Alkermes, & More

To get ready for the annual post-Labor Day market revival, three Boston-area biotechs have put their IPO plans on the front burner. Syndax Pharmaceuticals has come back to the table after postponing its plans earlier this year, while Rhythm Pharmaceuticals and Civitas have declared their intentions for the first time. In pipeline news, Alkermes has […]

Posted in Boston, National blog main, New York blog main, Raleigh-Durham blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Biogen, Civitas, Rhythm, Alkermes, & More

Xconomy Boston’s Top Stories of Q2 2014: Editor’s Picks

Here are my picks for our top local stories of the past quarter (April-June), and why. Not a ranked list, just in reverse chronological order: 1. MA Warns Ride-Sharing, Car-Sharing Drivers of Insurance Risks Could something as boring as insurance derail Uber? 2. Katrine Bosley, Former Avila CEO, Takes Helm at Editas Cutting-edge genomics company, […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Xconomy Boston’s Top Stories of Q2 2014: Editor’s Picks

East Coast Biotech Roundup: Concert, Merrimack, Vertex, & More

A near-death experience for an IPO, new life for a cancer drug company, and plenty of clinical trial results dot the roundup this week. Those stories and more below. —Lexington, MA-based Concert Pharmaceuticals (NASDAQ: CNCE) may have priced its IPO at the top of its range earlier this year, but not without a fair bit […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Concert, Merrimack, Vertex, & More

How A Kidney Drug Almost Torpedoed Concert Pharma’s IPO

[Updated, 4/27/14, 10:49 am ET] Drug development is a humbling thing. Hard as you might try, the numbers show that 90 percent of the time, you’ll fail. What if the signs of such a failure were to emerge, of all times, when you’re pitching an IPO? That’s just the situation that Concert Pharmaceuticals confronted last […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, Raleigh-Durham blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More

(Updated, 9:05 am ET) The East Coast got buried in snow this week—again—but biotech activity was raging regardless. More IPOs priced (of course). A new high-profile startup emerged from stealth. A small acquisition wowed Wall Street. Those headlines and more below: —Third Rock Ventures has had success so far with its first gene therapy portfolio […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More

Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share

What’s it worth to add a little deuterium to drugs to boost their abilities? In Wall Street’s eyes, about $14 per share. Lexington, MA-based Concert Pharmaceuticals will debut on the Nasdaq today after pricing its IPO at the top of its projected range of $14 per share. The company sold 6 million shares in the […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share

East Coast Biotech Roundup: JP Morgan Edition

[Updated, 9:05 am ET] The biotech world’s official state of the industry lollapalooza—the JP Morgan Healthcare Conference in San Francisco—has come and gone, and taken along with it the sunny weather, the wall to wall investor meetings, the jam-packed presentations, and the late-night cocktail parties (back to the polar vortex for all of us East […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: JP Morgan Edition

Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker

Celgene is best known for taking a notoriously dangerous compound, thalidomide, and turning a derivative into a hugely successful cancer drug. But what fewer people may realize is that it is fast building the biotech industry’s best network of partnerships with innovators. This feels odd to say, even though Celgene (NASDAQ: CELG) has been a […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, National, National blog main, National top stories, New York blog main, New York top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Trusting Your Partners: A Chat With Celgene’s George Golumbeski

It’s no secret that biotech IPOs, for the first time in at least 10 years, are suddenly white hot. Companies with sparse evidence from clinical trials, or those with drugs that have failed such trials, are finding success raising cash from public investors. But take a look at some of the best performing biotech IPOs […]

Posted in Boston blog main, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , , , , , | 2 Comments

East Coast Life Sciences Roundup: Dunsire, Good Start, Nimbus, & More

It was a busy week of big promise and big moves for biotechs on the East Coast. One biotech added to a string of partnerships and awaits results from a key mid-stage study for one of its own drugs. Another signed its first deal with Big Pharma. And one well-respected life sciences executive abruptly left. […]

Posted in Boston, Boston blog main, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Life Sciences Roundup: Dunsire, Good Start, Nimbus, & More← Older posts Newer posts →